查看文章

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has dramatically expedited global vaccine development efforts^{, –}, most targeting the viral ‘spike’ glycoprotein (S). S localizes on the virion surface and mediates recognition of cellular receptor angiotensin-converting enzyme 2 (ACE2)^{, –}. Eliciting neutralizing antibodies that block S–ACE2 interaction^{, –}, or indirectly prevent membrane fusion, constitute an attractive modality for vaccine-elicited protection. However, although prototypic S-based vaccines show promise in animal models^{, –}, the immunogenic properties of S in humans are poorly resolved. In this study, we characterized humoral and circulating follicular helper T cell (cTFH) immunity against spike in recovered patients with coronavirus disease 2019 (COVID-19). We found that S-specific antibodies, memory B cells and cTFH are consistently elicited after SARS-CoV-2 infection …